Xiaoyi Ye, MD
Nephrology · Hartford, CTNPI 1821279514
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,932 of the $25,045 with a category attached, or 71.6%. Sanofi accounts for 81.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $8,135 and has fallen 91.1% since, to $725 in 2025. Among nephrology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $362.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$20K
- AstraZeneca$1K
- Veloxis Pharmaceuticals, Inc.$692
- Sanofi-aventis U.S. LLC$664
- Mallinckrodt Hospital Products Inc.$427
- Astellas Pharma US Inc$411
- plus $1K from 12 others
What the payments were for
- Consulting fees$1,4346%
- Speaking & faculty fees$17,93272%
- Travel & lodging$6953%
- Food & beverage$4,54418%
- Education$4402%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 18 | $20,337 |
| AstraZeneca(2 entities) | 8 | $1,055 |
| Veloxis Pharmaceuticals, Inc. | 7 | $692 |
| Sanofi-aventis U.S. LLC | 9 | $664 |
| Mallinckrodt Hospital Products Inc. | 3 | $427 |
| Astellas Pharma US Inc | 4 | $411 |
| Baxter Healthcare | 3 | $381 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $243 |
| Dynavax Technologies Corporation | 2 | $223 |
| Gilead | 1 | $125 |
| Vifor Pharma, Inc. | 1 | $122 |
| AbbVie | 1 | $121 |
| Ardelyx, Inc. | 1 | $115 |
| Merck | 3 | $55 |
| Novo Nordisk | 1 | $33 |
| Novartis | 1 | $21 |
| Eisai Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 3 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$16,549
- Envarsus$608
- ULTOMIRIS$549
- TERLIVAZ$427
- THYMOGLOBULIN$364
- LIVTENCITY$243
- CRESEMBA$235
- FARXIGA$233
- Heplisav-B$223
- SOLIRIS$150
- Vemlidy$125
- Renal - Non Product Related$125
- Veltassa$122
- DALVANCE$121
- XPHOZAH 30 MG$115
How this compares
$25,045 in reported general payments places this provider in the 90th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 21 | $23,036 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 52 | $16,577 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $15,909 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $15,734 |
| Sevelamer Carbonate | 67 | $12,862 |
| Cinacalcet Hcl | 37 | $10,976 |
| Valganciclovir Hcl | 25 | $5,101 |
| Calcium Acetate | 47 | $3,879 |
| Entecavir | 41 | $3,185 |
| Prednisone | 251 | $1,183 |
| Tacrolimus | 15 | $1,126 |
| Labetalol Hcl | 36 | $1,123 |
| Hydralazine Hcl | 62 | $1,048 |
| Metoprolol Succinate | 65 | $815 |
| Amlodipine Besylate | 108 | $608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,055 | $38,94541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 nephrology providers in Connecticut.
Other nephrology in Hartford
- Terrence OderHartford$1K
- Robert AlpernNew Haven$4.9M
- Ari GellerBloomfield$209K
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- James GavinTrumbull$103K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- David SimonOrange$59K
- Ladan GolestanehNew Haven$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.